Compare Stocks → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADMPNYSE:ANVSNASDAQ:BLPHNASDAQ:JAGXNASDAQ:MBRX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMPAdamis Pharmaceuticals$1.28$0.75▼$26.18$7.26M1.27811,695 shs119,800 shsANVSAnnovis Bio$10.06+2.1%$10.36$5.42▼$22.49$110.76M1.59265,139 shs224,080 shsBLPHBellerophon Therapeutics$0.05$0.05$0.03▼$11.15$665K0.6763,011 shs53,937 shsJAGXJaguar Health$0.16-11.3%$0.09$0.05▼$1.22$43.34M1.3550.67 million shs31.20 million shsMBRXMoleculin Biotech$4.65+2.9%$7.07$4.28▼$15.75$10.37M1.9530,571 shs10,562 shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMPAdamis Pharmaceuticals0.00%0.00%0.00%0.00%-88.34%ANVSAnnovis Bio+8.93%-19.02%+9.78%-15.48%-33.24%BLPHBellerophon Therapeutics+4.77%+7.53%+8.97%-7.15%-99.42%JAGXJaguar Health+7.40%+64.74%+157.04%+74.83%-72.32%MBRXMoleculin Biotech+6.07%-5.02%-42.22%-44.66%-62.17%Tiny Biotech Stock Wins $75 Billion Patent (Ad)A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.Find out more here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AANVSAnnovis Bio1.6543 of 5 stars3.41.00.00.03.11.70.6BLPHBellerophon Therapeutics1.8282 of 5 stars3.00.00.04.82.60.00.6JAGXJaguar HealthN/AN/AN/AN/AN/AN/AN/AN/AMBRXMoleculin Biotech2.278 of 5 stars3.53.00.00.02.90.01.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMPAdamis PharmaceuticalsN/AN/AN/AN/AANVSAnnovis Bio2.75Moderate Buy$27.75175.84% UpsideBLPHBellerophon Therapeutics2.00Hold$2.003,576.47% UpsideJAGXJaguar HealthN/AN/AN/AN/AMBRXMoleculin Biotech3.00Buy$35.00652.69% UpsideCurrent Analyst RatingsLatest ANVS, MBRX, BLPH, JAGX, and ADMP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024MBRXMoleculin BiotechRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.004/2/2024ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.003/26/2024MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $20.003/21/2024ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.002/28/2024ANVSAnnovis BioBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$9.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMPAdamis Pharmaceuticals$4.76M0.00N/AN/A($1.26) per share0.00ANVSAnnovis BioN/AN/AN/AN/A($0.73) per shareN/ABLPHBellerophon Therapeutics$5.64M0.12N/AN/A$0.27 per share0.20JAGXJaguar Health$9.76M4.44N/AN/A$0.07 per share2.24MBRXMoleculin BiotechN/AN/AN/AN/A$11.70 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMPAdamis Pharmaceuticals-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/AANVSAnnovis Bio-$56.20M-$6.22N/AN/AN/AN/A-446.06%-257.97%5/9/2024 (Estimated)BLPHBellerophon Therapeutics-$19.83M-$0.84N/A∞N/AN/A-187.35%-104.97%5/13/2024 (Estimated)JAGXJaguar Health-$41.30MN/A0.00∞N/A-423.11%-837.11%-80.76%5/20/2024 (Estimated)MBRXMoleculin Biotech-$29.77M-$13.64N/AN/AN/AN/A-80.91%-67.69%5/9/2024 (Estimated)Latest ANVS, MBRX, BLPH, JAGX, and ADMP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/19/2024N/ABLPHBellerophon TherapeuticsN/A-$0.42-$0.42N/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/ABLPHBellerophon TherapeuticsN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMPAdamis PharmaceuticalsN/A0.230.19ANVSAnnovis BioN/A2.392.39BLPHBellerophon TherapeuticsN/A3.963.96JAGXJaguar Health6.332.001.34MBRXMoleculin BiotechN/A3.863.86OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMPAdamis Pharmaceuticals38.55%ANVSAnnovis Bio15.83%BLPHBellerophon Therapeutics10.61%JAGXJaguar Health12.04%MBRXMoleculin Biotech15.52%Insider OwnershipCompanyInsider OwnershipADMPAdamis Pharmaceuticals1.30%ANVSAnnovis Bio38.30%BLPHBellerophon Therapeutics5.20%JAGXJaguar Health0.16%MBRXMoleculin Biotech6.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADMPAdamis Pharmaceuticals119.36 million9.24 millionOptionableANVSAnnovis Bio511.01 million6.79 millionOptionableBLPHBellerophon Therapeutics1812.23 million11.60 millionOptionableJAGXJaguar Health49276.22 million275.77 millionNo DataMBRXMoleculin Biotech182.23 million2.08 millionNot OptionableANVS, MBRX, BLPH, JAGX, and ADMP HeadlinesSourceHeadlineMoleculin Biotech Says EMA Grants Orphan Drug Designation To Annamycin To Treat AMLmarkets.businessinsider.com - April 18 at 9:42 AMEuropean Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)prnewswire.com - April 18 at 8:30 AMRoth Mkm Reiterates Buy Rating for Moleculin Biotech (NASDAQ:MBRX)americanbankingnews.com - April 14 at 1:58 AMMoleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.comamericanbankingnews.com - April 13 at 2:22 AMMoleculin Biotech Inc (MBRX)investing.com - April 12 at 12:07 AMMoleculin Biotech Reveals Positive Anti-cancer Data For Annamycin With Non-cardiotoxic Effectsmarkets.businessinsider.com - April 10 at 12:17 PMMoleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Propertiesprnewswire.com - April 10 at 8:30 AMMoleculin to Present at the MedInvest Biotech & Pharma Investor Conferencefinance.yahoo.com - March 28 at 11:23 AMMoleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AMLfinance.yahoo.com - March 27 at 1:35 PMMoleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunityprnewswire.com - March 27 at 9:25 AMMoleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 26 at 9:48 AMNews - Moleculin Biotechthepharmaletter.com - March 25 at 11:47 PMMoleculin Biotech, Inc.: Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trialfinanznachrichten.de - March 25 at 6:45 PMMoleculin skyrockets on interim data for annamycin MB-106 trialthepharmaletter.com - March 25 at 6:45 PMMoleculin Biotech Reports Positive Interim Data From MB-106 Phase 1B/2 Study In AMLmarkets.businessinsider.com - March 25 at 9:05 AMMoleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trialfinance.yahoo.com - March 25 at 9:05 AMMoleculin Biotech, Inc.: Moleculin Reports Full Year 2023 Financial Resultsfinanznachrichten.de - March 23 at 10:20 AMMBRX Stock Earnings: Moleculin Biotech Reported Results for Q4 2023investorplace.com - March 22 at 10:03 PMMoleculin Biotech Inc Reports Fiscal Year 2023 Financial Resultsfinance.yahoo.com - March 22 at 7:18 PMMoleculin Reports Full Year 2023 Financial Resultsprnewswire.com - March 22 at 4:05 PMMoleculin Biotech announces 1-for-15 reverse stock splitinvesting.com - March 21 at 11:00 PMA Preview Of Moleculin Biotech's Earningsbenzinga.com - March 21 at 5:59 PMMoleculin Biotech, Inc.: Moleculin Announces Reverse Stock Splitfinanznachrichten.de - March 20 at 1:07 PMMoleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcastprnewswire.com - March 20 at 7:30 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAdamis PharmaceuticalsNASDAQ:ADMPAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.Annovis BioNYSE:ANVSAnnovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.Bellerophon TherapeuticsNASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Jaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.Moleculin BiotechNASDAQ:MBRXMoleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.